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Abstract  
Aim: To determine the therapeutic potential of Manuka honey against NDM-1 producing K. 
pneumoniae ST11 in vitro and in vivo. Materials and Methods: Carbapenamases and MBLs 
producing K. pneumoniae ST11 isolated from blood culture was confirmed by Vitek 2, 
MALDI-TOF, MLST and MIC (µg/mL) was performed by Vitek 2 system. Genetic analysis 
of blaNDM-1 was done by PCR, PFGE and DNA hybridization. In vitro and in vivo efficacy of 
Manuka honey was performed by microbroth dilution assay and BALB/c mice respectively. 
Results: K. penumoniae ST11 displayed resistance to commonly used antibiotics. blaNDM-1 
was located on 150kb of plasmids. MIC and MBC of Manuka honey was 30% (v/v) and 
substantial reduction of bacterial mean log value (>1log) was observed in mouse model. 
Histological analysis of mice liver and kidneys demonstrated mild to moderate inflammation. 
Conclusion: Manuka honey can be used as alternate therapeutic approach for the 
management of NDM producing pathogens. 
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Introduction  
New Delhi Metallo-β-lactamase (NDM) is an emerging type of carbapenamase belongs to the 
B1 super family of metallo-β-lactamases (MBLs) are rapidly spreading globally [1]. NDM 
was first identified from Escherichia coli and Klebsiella pneumoniae isolated from a Swedish 
patient who had been hospitalized and sought medical care in New Delhi, India [2]. NDM 
producing pathogens confer resistance against a wide range of antibiotics including 
aminoglycosides, quinolones, monobactam and most notably β-lactam drugs including 
carbapenems; considering last resort to treat extensively drug resistant (XDR) pathogens [3].  
NDM producing bacteria are responsible for high rate of mortality in our clinical settings. 
Previously, we reported that 4/9 pediatrics who had been hospitalized in Islamabad, Pakistan 
died due to NDM producing bacteria [4]. Recently, another study revealed that 57% and 
60% adult and neonatal patients died respectively in Karachi, Pakistan and the chief pathogen 
was NDM-1 positive K. penumoniae [5]. NDM producing pathogens confer resistance 
against a wide range of antibiotics including aminoglycosides, quinolones, monobactam 
and most notably β-lactam drugs including carbapenems; considering last resort to 
treat extensively drug resistant (XDR) pathogens and no or few treatment options available 
[3]. Therefore, therapeutic management of NDM producing bacteria is becoming a big 
challenge worldwide. Over the century, there is a huge production and development of 
synthetic drugs to improve the health care problems however, many countries still rely 
on their traditional medicine like honey as a primary care [6]. 
Manuka honey is one the widely used medicinal honey for wound dressing worldwide. Its 
antibacterial activity is mainly due to the presence of methylglyoxal (MGO) compound apart 
from acidic pH, high osmotic pressure, immune stimulant and the presence of trace elements 
[7]. Hence, Manuka honey is promising for the extensive cell lysis of bacteria and it is hard to 
believe that bacteria produce resistance against its multi-directional effects because it 
contains a combination of different compounds that may act synergistically to 
overcome antibacterial resistance. Previously, there are several in vitro studies have been 
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reported in different regions on the antibacterial nature of Manuka honey against multi-drug 
resistant (MDR) pathogens [8-10]. In our previous study, we produced septicemia in BALB/c 
model following the methicillin resistant Staphylococcus aureus (MRSA) infection and treat 
them with Manuka honey intravenously (data not published). All the mice 
were recuperated, and no mice mortality were noticed [11]. As per our knowledge, there is no 
data available on the efficacy of Manuka honey against the NDM producing pathogens in 
mouse model. 
Therefore, this study aimed to determine in vitro and in vivo activity of Manuka honey 
against the NDM-1 producing K. pneumoniae sequence type (ST) 11.  
Materials and Methods  
Identification and confirmation of bacterial strain  
Klebsiella pneumoniae isolated from blood culture was collected from a tertiary care hospital 
Lahore. Bacterial isolate was sub-cultured on blood, MacConkey and UTI CHROMagar™ 
and plates were incubated at 37°C overnight. Preliminary identification was done based on 
colony morphology and cultural characteristics. Biochemical identification was done by 
utilizing 64 different biochemical tests on VITEK® 2 system (bioMérieux, France) using GN 
ID cards and peptide base bacterial confirmation was done by matrix assisted lase desorption 
ionization time of flight (MALDI-TOF) (Bruker Daltonics, Germany). 
 
Sequencing typing (ST) of K. pneumoniae  
Multilocus sequence typing (MLST) of K. pneumoniae was done by amplifying seven 
housekeeping genes including, rpoB (beta-subunit of RNA polymerase), gapA 
(glyceraldehyde-3-phosphate dehydrogenase), mdh (malate dehydrogenase), pgi 
(phosphoglucose isomerase), phoE (phosphorene E), infB (translation ignition factor 2), tonB 
(periplasmic energy transducer) by multiplex PCR as describe earlier [12]. PCR products 
were visualized on ethidium bromide stained agarose gel and product sizes were compared 
with ladder. Amplicons were extracted from gel using commercially available QIAquick Gel 
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extraction kit (QIAGEN, Germany) and sequenced by Eurofins Scientific Company, UK. 
After sequencing, data of seven genes were analyzed using Institute Pasteur MLST K. 
penumoniae database [13].  
Antimicrobial susceptibility testing 
MIC (µg/mL) of the K. penumoniae was performed using AST-XN 05 cards in VITEK®2 
compact instrument (bioMerieux, France) against 18 different antibiotics including 
Ampicillin/Sulbactam, Ticarcillin/Clavulanic Acid, Piperacillin, Cefuroxime, Cefuroxime 
axetil, Cefixime, Ceftriaxone, Cefepime, Aztreonam, Meropenem, Levofloxacin, 
Moxifloxacin, Minocycline, Tetracycline, Tigecycline, Chloramphenicol, Colistin and 
Trimethoprim. Results were interpreted as per Clinical Laboratory Standard Institute (CLSI) 
2015 guidelines [14]. MIC (µg/mL) is the lowest concentration of an antibiotic that inhibits 
the growth of bacteria.   
Phenotypic detection of carbapenamases  
Carbapenamase detection was done using Modified Hodge’s test (MHT) as per CLSI 2015 
guidelines. Briefly, 0.5McFarland E. coli (ATCC 25922) lawned on Mueller Hinton agar 
(MHA) plate. A meropenem (10µg) disc was placed centrally and test organism, positive and 
negative control were streaked from edge of the disc to the edge of the MHA plate. 
Carbapenamases positive bacteria permit the meropenem sensitive E. coli (ATCC 25922) to 
grow against the meropenem disc which lead to a cloverleaf like indentation [14].   
Phenotypic detection of Metallo-β-lactamases (MBLs) 
MBLs detection was done by double disc synergy method. In short, MBLs belong to the class 
B of β-lactamases which require Zn+2 as a cofactor for their enzymatic activity. Their 
functional activity can be lost by treating them with a chelating agent such as ethylene 
diamine tetra acetic acid (EDTA). Briefly, 0.5McFraland bacterial suspension was lawned on 
the MHA plate. Two meropenem (10µg) and two ertapenem (10µg) discs were placed and 
0.5M EDTA solution was added on one meropenem and ertapenem disc. Bacteria was MBLs 
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producer if the EDTA discs showed >5mm zone of inhibition as compare to non EDTA discs 
[15]. 
Molecular identification of blaNDM-1 
Bacterial DNA extracted by commercially available bacterial genomic DNA kit TIANamp 
(China). blaNDM was identified using specific primers: NDM-F 5ʹ-
ATGGAATTGCCCAATATTATGCAC-3ʹ and NDM-R 5ʹ-TCAGCGCAGCTTGTCGGC-3ʹ 
using following conditions; initial denaturation: 95°C for 1 min, secondary denaturation: 
95°C for 45 sec, annealing: 58°C for 45 sec, primary extension: 72°C for 1 min and final 
extension: 72°C for 5min and ∞ at 4°C. Amplicon was separated on ethidium bromide 
stained agarose gel using horizontal electrophoresis and product size was compared with 
DNA ladder.  
Sequencing 
Furthermore, blaNDM was re-amplified by employing another set of primers (NDMV-F 5ʹ-
TGGCTTTTGAAACTGTCGCACC-3ʹ and NDMV-R 5ʹ-
CTGTCACATCGAAATCGCGCGA-3ʹ). These primers were designed upstream and 
downstream of the gene to ensure the entire gene was sequenced. DNA sequence was 
analyzed by Geneious software [16] and aligned sequence was submitted to GenBank using 
BankIt software [17] for accession number allotment. 
Plasmid characterization  
Diversity of plasmids and blaNDM-1 location was done by S1 nuclease pulse field gel 
electrophoresis (PFGE) and DNA hybridization respectively as described previously [18].  
Agar well diffusion assay  
Manuka honey was purchased from ManukaPharm®, Leicestershire, UK with +20 Unique 
Manuka Factor (+20UMF) which contained approximately 800mg/kg MGO [19].  MGO is an 
active component of the Manuka honey which is formed by nectar derived dihydroxyacetone 
during ripening. Antibacterial activity of undiluted Manuka honey (+20UMF) was performed 
by agar well diffusion assay against NDM-1 positive K. pneumoniae, adopted from punch 
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plate assay. In short, 0.5McFarland bacterial suspension was inoculated on MHA plate and 
sterile 6mm cork borer used to make wells on each plate. Subsequently, 120µL undiluted 
Manuka honey was poured in each well and plates were incubated at 37°C overnight. Zone of 
inhibition (mm) was measured by Vernier caliber. The assay was performed in triplicate [20].   
Minimum inhibitory concentration (MIC) of Manuka honey 
Microbroth dilution assay was used to determine the MIC (%v/v) and minimum bactericidal 
concentration (MBC %v/v) of the Manuka honey [21]. Two to three isolated colonies were 
mixed in 20mL of double strength Lysogeny broth (LB) medium in 50mL of falcon tube and 
incubated at 37°C overnight. Bacterial suspension was diluted to achieve 0.5Mcfarland at OD 
of 0.07 at 600nm spectrophotometrically. Bacterial suspension was further diluted 1:100 with 
double strength LB broth to achieve a final concentration of 1x 105 CFU/mL. Briefly, serial 
dilutions of Manuka honey (5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45% and 50%) 
were prepared in sterile distilled deionized water and 100µL of each honey dilution was 
added in 96-wells, flat bottom micro titer plates (Thermo Fisher Scientific, UK). 
Subsequently, 100µL of bacterial suspension was added into each well. Negative control 
wells contained 100µL of LB broth and positive control wells contained LB medium 
inoculated with bacteria suspension. Microtiter plate was incubated at 37°C overnight at 
shaking incubator (MaxQTM Mini 4450) at 3g. MIC was calculated by comparing each well 
with negative and positive control wells. All the procedure was performed in triplicate.   
Minimum bactericidal concentration (MBC) determination  
MBC is defined as first dilution with no growth on agar plate. A 10µL sample was taken from 
the no visible growth wells of microtiter plate and was inoculated on the nutrient agar plates 
(Oxoid, UK) and aerobically incubated at 37°C for 24 hours. Plates were examined for cell 
viability. Any colonies that developed were scored as bacterial growth and no bacterial 
growth. All the procedures repeated in triplicate.   
Animals and experimental groups: 
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Before staring the clinical experiment, permission was taken by the Ethical Review 
Committee for Medical and Biomedical Research, University of Health Sciences, Lahore, 
Pakistan.    
BALB/c mice between the ages of 12-14 weeks, weighing 30-35 grams were used from the 
Animal Facility, University of Health Sciences, Lahore, Pakistan. All the mice kept in cages 
containing sawdust and wood shavings as litter material. Animal room temperature was 
maintained at 25±2°C and provided with 12 hours light and dark cycles. They were given 14 
days adaptation period and during this interval they were screened for any infections or 
abnormalities. They were kept on standard balance diet for rodents and fresh potable water ad 
libitum [22]. 
Experimental work for in vivo activity of Manuka honey   
Mice were divided into five different experimental groups; A (negative control, non-infected 
mice), B (positive control, infected mice), C (infected mice treated with 20% Manuka honey), 
D (infected mice treated with 30% Manuka honey) and E (infected mice treated with 
tigecycline) and each group comprised of eight mice. Mice of Groups B, C, D and E were 
challenged with 100µL of 1x105 CFU of NDM-1 K. pneumoniae ST11 strain through lateral 
tail vein to produce systemic infection [23] and observed for any clinical signs and 
symptoms. However, Group B mice were not treated with any therapeutic agent and blood 
culture was performed to establish the bacteremia in BACTEC 9120 (Becton Dickinson 
Diagnostic Instrument System, Spark, Md) instrument. After 3 hours post infection, mice of 
Group C and D were treated with 200µL of 20% and 30% (v/v) Manuka honey through 
lateral tail vein respectively with an interval of 12 hours for next two weeks [11]. Blood 
culture was performed on 7th and 15th day post treatment for bacterial count (CFU). However, 
mice of Group E administered 5mg/kg intravenous injection of tigecycline (Pfizer, 
Laboratories, USA) twice a day after 3 hours post infection and treated for seven days [24] 
and blood culture was performed on seven days for CFU.  
Blood culture and bacterial count 
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Blood (0.1mL) was drawn from the lateral tail vein of each mice using aseptic technique. 
Blood was immediately inoculated into blood culture bottle (BD Peds plus/F) and processed 
in BACTEC 9120 (Becton Dickinson Diagnostic Instrument System, Spark, Md). Positive 
specimens were sub-cultured on blood agar and incubated at 37°C overnight. K. pneumoniae 
was re-identified using VITEK 2 system (BioMerieux, France). Bacteria (CFU) were 
calculated by Miles and Misra method. 
Histological analysis   
All the experimental mice (Group C and D) and control mice (Group A) were anesthetized 
and sacrificed according to standard operating procedures. Mice kidneys, liver and spleen 
were surgically removed and fixed in 10% formaldehyde, embedded in paraffin wax and 
stained with hematoxylin and eosin (H/E). Microscopic analysis was performed by the 
qualified histopathologist and reports were interpreted by scoring as mild, moderate and 
sever.   
Statistical Analysis 
All statistical analysis was done using statistical package for social sciences (SPSS) software 
(version 22). Numerical data were determined using mean ± SD. One-way ANOVA was 
applied to determine the mean differences (bacterial count) among the groups. Tukey test and 
Chi-square/ Fishers test were used to compare the categorical data among groups. P value ≤ 
0.05 will be considered as significant.   
Results  
Molecular characterization and identification:  
NDM-1 producing Klebsiella pneumoniae spp pneumoniae which belongs to the ST11 was 
confirmed after multi sequence alignment (Accession no. KY446367) and MLST analysis 
respectively. Moreover, plasmid characterization revealed that isolate contained five different 
sizes of plasmids (~80, 100, 150, 200 and 270 kb) and blaNDM was located on 150kb and 
270kb of plasmids. Furthermore, K. pneumoniae was also capable to produce carbapenamase 
and MBLs (Figure 1 and 2). 
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Antibiogram profiling:  
MIC (µg/mL) of the K. pneumoniae displayed 100% resistance against β-lactam antibiotics 
and β-lactam inhibitors however, minocycline (8µg/mL) and trimethoprim (8µg/mL) 
exhibited intermediate resistance, while most effective drugs were colistin and tigecycline 
(≤0.5µg/mL) (Table 1). 
In vitro efficacy of Manuka honey: 
Concentrated Manuka honey displayed limited antibacterial activity with an average zone of 
inhibition of 9mm± 0.0 SD by agar well diffusion assay (Figure 3). However, K. pneumoniae 
was inhibited and killed at 30% v/v of Manuka honey by microbroth dilution assay.     
In vivo activity of Manuka honey: 
In general, mice of Group A (negative control) remained clinically healthy during the whole 
span of trial. However, after the bacterial inoculation, all the mice of Group B, C, D and E 
developed severity of clinical signs and symptoms of infection including lack of alertness, 
lack of movement, piloerection, conjunctival injection/mucky eyes and hunched backs. 
Following the treatment with antibiotic, all the mice of Group E were fully recovered after 
one week with no apparent clinical symptoms while substantial clinical improvement was 
observed in the mice of Group C and D post-treatment with 20% and 30% Manuka honey 
respectively. Furthermore, no mice mortality occurred during the clinical trial.  
Mean log value for Group B (positive control) animals was 2.744 after one week of infection 
that was increased to 3.238 during the second week. However, mean log value for Group C 
(treated with 20% Manuka honey) mice was 1.829 after 7 days that was reduced to 1.035 at 
the end of second week. Similar trends were observed in Group D (treated with 30% Manuka 
honey) mice in which mean log value was substantially decreased from 1.624 to 0.610 in first 
and second week respectively (Figure 4). One-way ANOVA indicated statistically significant 
differences among treatment groups (F=74.326, P- <0.0001) and effects of interaction 
between treatment and mean duration period (F=8.614, P- <0.0001) which suggested that 
continuous treatment for extended period had negative effect on mean CFU count. However, 
10 
 
 
 
 
 
no significant effect was observed on treatment period alone. Tukey (HSD) test showed 
significant differences among different mice groups. They were statistically highly significant 
(P- <0.0001) when compared to positive control (Group B). Similarly, CFU count from mice 
Group E (treated with antibiotic) was also statistically highly significant (P- <0.0001) when 
compared with Group B, C and D. However, no statistical difference was observed between 
mice Group C and D (P- 0.384). 
Histopathological analysis of Manuka honey treated groups:   
Liver of Group C and D mice   
The liver cells of the Group A (negative control) animals had normal histological 
morphology however, hepatocytes of the Group C and D mice harboring lobules and 
trabeculae having round centrally placed nuclei and moderate amount of eosinophilic 
granular cytoplasm. While, moderate number of inflammatory cells infiltrated lobules 
especially around central vein which are predominantly composed of lymphocytes and few 
neutrophils. Moreover, few sinusoids were dilated along with lymphoid aggregates and focal 
areas of spotty necrosis were also evident. However, no portal tracts were seen (Figure 5). 
Overall, no distinctive cytological changes in liver cells of Group C and D mice were 
observed.    
Kidney of Group C and D mice: 
Renal cells of the control mice exhibited normal histology profile however, H/E section of 
the Group C and D mice revealed that interstitium showed mild infiltration of inflammatory 
cell including lymphocytes and few neutrophils. Furthermore, normal renal parenchyma 
composed of glomeruli and tubules while few glomeruli were sclerosed. Surrounding tubules 
were lined by cuboidal epithelial cells having regular nuclei and granular eosinophilic 
cytoplasm. In general, both the mice Groups displayed benign renal tissue with non-specific 
inflammation (Figure 6).  
Spleen of Group C and D mice 
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The spleen cells of the control group exhibited normal cellular morphology. Although, spleen 
of the Group C and D mice presented numerous scattered multinucleated giant cells, bizarre 
cells and increased mitotic activity. Areas of hemorrhage and sheets of lymphocytes were 
also noticed (Figure 7).  
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Discussion  
Rapid dissemination of NDM producing pathogens is becoming a big challenge worldwide. 
Although Indian subcontinent is the main reservoir for NDM-1 producing 
Enterobacteriaceae but several cases also reported from the Balkan State. NDM gene is 
mainly located on plasmids and easily transferable among bacterial population. In present 
study, we characterized NDM-1 producing K. pneumoniae which belongs to the ST11. 
Similar findings have been documented from different regions including India, UK and 
Sweden [25, 26], USA [27] and Poland [28]. However, as per our knowledge we are first 
time reporting NDM-1 positive K. pneumoniae ST11 in Pakistan. Spread of this clinical 
pathogen in our clinical setting is mainly due to the poor health care management, unhygienic 
practices, overcrowded wards and hospitals, cross contamination due to sharing beds and use 
of contaminated intravenous catheter [29]. Genetic characterization of the isolate revealed 
presence of blaNDM on ~150kb and ~270kb plasmids. Previous studies from Bangladesh, India 
and UK documented the presence of blaNDM on the transmissible plasmids ranging from 80kb 
to 500kb in Enterobacteriaceae family [3, 30]. MIC of the isolate depicted high resistance 
not only against β-lactam drugs but also other classes of antibiotics and most effective drugs 
were colistin and tigecycline. These findings are in accordance with our previous study on the 
spread of NDM-1 in pediatric patients in Pakistan [4]. Furthermore, studies from Pakistan, 
India and UK also reported almost similar findings and colistin was the drug of choice [3, 5, 
31]. This resistance is directly linked to the irrational and broad spectrum use of antibiotics in 
our clinical settings, other important factors includes self-medication and free access to 
antibiotics at pharmacy corner [29].  
According to previous studies, Manuka honey exhibited bacteriogenic activity against 
different MDR pathogens including ESBL producing K. pneumoniae (30%-40%v/v) [32], P. 
aeruginosa (12%v/v) [33] and A. baumannii (12.5%v/v) [34]. In current study, 30%v/v 
Manuka honey is sufficient to inhibit and kill NDM-1 producing K. pneumoniae ST11. In our 
knowledge, there is no data available on the antibacterial activity of honey against the NDM-
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1 positive K. pneumoniae ST11 so far. In this study, we have analyzed the in vivo activity of 
Manuka honey against the NDM-1 positive K. pneumoniae strain (Figure 4). As per our 
knowledge, there is no data available on the intravenous use of Manuka honey in mouse 
model infected with NDM positive K. pneumoniae strain so far. However, one of our 
previous study documented the intravenous administration of Manuka honey completely 
recovered the MRSA infected mice with no mouse mortality [11]. Moreover, Al-Waili et al 
reported the intravenous inoculation of honey in sheep which presented a significant 
improvement in lipid profile, renal profile and other proteins [35]. Intravenous injection of 
Manuka honey lead to substantial reduction of bacterial load in a time dependent manner in 
present study. Overall, 20%v/v honey treatment resulted in ≥1 log reduction of the bacterial 
CFU, while 30%v/v caused 1-2 log bacteria reduction. In comparison to study conducted on 
MRSA infected mice [11], Manuka honey treatment was unable to fully recover bacteremia 
induced by K. pneumoniae may be attributed to its stringent nature. Surprisingly, 
histopathological studies revealed mild to moderated morphological changes in liver, kidneys 
and spleen after honey treatment. In contrary, a study from Pakistan depicted that high oral 
dose of Manuka honey to treat MRSA leads to severe histological changes of the kidney cells 
including focal tubular epithelial cell degeneration and coagulative necrosis [36]. As per our 
knowledge there is no data available on the histological effect of Manuka honey against 
NDM producing K. pneumoniae ST11 so far.          
Conclusion  
This study conclude that Manuka honey has a potential effect on the NDM-1 producing K. 
pneumoniae both in vitro and in vivo. Therefore, Manuka honey can be used as a substitute or 
in combination with antibiotics to treat the infections caused by such pathogens after several 
clinical trials.  
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Table 1: MIC (µg/mL) of NDM-1 producing K. pneumoniae ST11 
 
Isolat
e 
SAM 
≤2 - 
≥32 
PIP 
≤4 - 
≥128 
CXM 
≤1 – 
≥64 
CXA 
≤1 – 
≥64 
CFM 
≤0.25 
- ≥4 
CRO 
≤1 – 
≥64 
FEP 
≤2 – 
≥64 
ATM 
≤1 - 
≥64 
MEM 
≤0.5 - 
≥16 
LEV 
≤0.12- 
≥8 
MXF 
≤0.25 
- ≥8 
MNO 
≤1 - 
≥16 
TE 
≤1 - 
≥16 
TMP 
≤0.5 - 
≥16 
C 
≤2 - 
≥64 
TGC 
≤0.5 - 
≥8 
CS 
≤0.5 - 
≥16 
NDM-
1 
produc
ing K. 
pneum
oniae 
ST11 
≥32 ≥128 ≥64 ≥64 ≥4 ≥64 ≥64 ≥64 ≥16 ≥8 ≥8 8 ≥16 8 4 ≤0.5 ≤0.5 
SAM: Ampicillin/Sulbactam, PIP: Piperacillin, CXM: Cefuroxime, CXA: Cefuroxime 
Axetil, CFM: Cefixime, CRO: Ceftriaxone, FEP: Cefepime, ATM: Aztreonam, MEM: 
Meropenem, LEV: Levofloxacin, MXF: Moxifloxacin, MNO: Minocycline, TE: 
Tetracycline, TMP: Trimethoprim, C: Chloramphenicol, TGC: Tigecycline, CS: Colistin,  
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Figure 1: Modified Hodge’s test for carbapenamase detection. Black arrows shows the 
cloverleaf like indetaion. T: test organism; P: positive control (known carbapenmase 
producing K. pneumoniae); N: negative control (E. coli ATCC 25922).  
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Figure 2: Double disc synergy method for MBLs detection. EDTA containing antibiotic 
discs shows >5mm zone of inhibition as compare to the non EDTA discs.   
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Figure 3: Agar well diffusion assay. White arrows indicate the zone of inhibition (mm) of 
Manuka honey against K. pneumoniae strain in triplicate.   
 
 
 
  
18 
 
 
 
 
 
 
Figure 4 shows the first and second week of intravenous treatment of mice against different 
mice groups.  
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Figure 5: Histological analysis of mice hepatocytes; A: normal control, B: 20% Manuka 
honey; C: 30% Manuka honey (HPFx40). 
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Figure 6: Histological examination of mice kidneys cells. A: 20% Manuka honey; B: 30% 
Manuka honey (HPFx40).   
A 
B 
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Figure 7: Histological results of mice spleen cells. A: 20% Manuka honey; B: 30% Manuka 
honey (HPFx40).  
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Summary points 
• In developing countries, New Delhi metallo-β-lactamase producing Klebsiella 
penumoniae is a serious threat in public health sectors.  
• These bacteria are difficult to treat due to the acquisition of blaNDM-1 which showed 
resistance against several antibiotics including carbapenems.  
• Manuka honey is a medicinal honey widely used to treat MDR pathogens, hence, we 
first time used Manuka honey to treat such bugs in vitro as well in vivo.  
Results: 
• NDM-1 producing K. pneumoniae ST11 was confirmed and blaNDM-1 was located on 
150kb and 270kb of plasmids.  
• MIC (µg/mL) of the K. pneumoniae displayed 100% resistance to wide range of 
antibiotics including carbapenems and most effective drugs were tigecycline and 
colistin. 
• In vitro, Manuka honey exhibited 9mm ±SD zone of inhibition while MIC (%v/v) and 
MBC (%v/v) was 30% against NDM-1 producing bug.  
• In vivo, there was a substantial reduction of bacterial mean log (>1 log) following the 
two weeks of Manuka honey treatment while mild to moderate inflammation was 
observed in liver and spleen of the mice.  
Conclusion: 
The study determined that Manuka honey could be used as a therapeutic agent to treat NDM 
producing K. pneumoniae ST11 after several clinical trials in vitro and in vivo. 
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